Difference between revisions of "Pomalidomide (Pomalyst)"
m |
|||
| Line 21: | Line 21: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *2/8/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm338895.htm Approved] for treatment of [[multiple myeloma]] in patients who received at least two previous therapies including [[Lenalidomide (Revlimid)]] and [[Bortezomib (Velcade)]] who have progressive disease within 60 days of the completion of the last therapy | + | *2/8/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm338895.htm Approved] for treatment of [[multiple myeloma]] in patients who received at least two previous therapies including [[Lenalidomide (Revlimid)]] and [[Bortezomib (Velcade)]] who have progressive disease within 60 days of the completion of the last therapy. ''(Based on NIMBUS & CC-4047-MM-002)'' |
| − | *5/14/2020: Approval expanded to include treating adult patients with AIDS-related [[Kaposi sarcoma]] after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative. ''(New disease entity)'' | + | *5/14/2020: Approval expanded to include treating adult patients with AIDS-related [[Kaposi sarcoma]] after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative. ''(New disease entity; based on NCI 12-C-0047)'' |
==Also known as== | ==Also known as== | ||
Revision as of 17:13, 25 May 2021
General information
Class/mechanism: Second-generation immunomodulatory drug (IMiD)--a thalidomide analogue--with antineoplastic activity. Pomalidomide has been shown to inhibit growth and induce apoptosis of hematopoietic tumor cells, enhance natural killer (NK) and T-cell cell-mediated immunity, and suppress monocyte production of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).[1][2][3]
Route: PO
Extravasation: n/a
- Use of Pomalidomide (Pomalyst) requires participation in the Pomalyst REMS program
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Pomalidomide (Pomalyst) package insert[1]
- Pomalidomide (Pomalyst) patient drug information (Chemocare)[4]
- Pomalidomide (Pomalyst) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2/8/2013: Approved for treatment of multiple myeloma in patients who received at least two previous therapies including Lenalidomide (Revlimid) and Bortezomib (Velcade) who have progressive disease within 60 days of the completion of the last therapy. (Based on NIMBUS & CC-4047-MM-002)
- 5/14/2020: Approval expanded to include treating adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative. (New disease entity; based on NCI 12-C-0047)
Also known as
- Code names: CC4047, CC-4047
- Generic name: 3-amino-thalidomide
- Brand names: Actimid, Ibipolid, Imnovid, Pomalid, Pomalyst